MPSS Technology Allows for Discovery of Micro RNAs (miRNA) and Small Interfering RNAs (siRNA) in Any Organism
Lynx Therapeutics, Inc.
(NASDAQ:LYNX) today announced the
National Science Foundation (NSF) has awarded a research
grant to the University of
Delaware to utilize Lynx's Massively Parallel Signature
Sequencing (MPSS(TM)) technology to develop methods to capture
and sequence small (21 to 24 ribonucleotides) RNAs on a larger
scale than previously possible. This new application will allow
researchers to simultaneously discover novel small RNAs and
quantify their expression patterns. These non-coding RNAs are
primarily involved in degradation of messenger RNAs, but also
function in the inhibition of translation and direct silencing
of genes via the methylation of genomic DNA. Recent advances in
silencing RNA have illustrated important biological roles for
siRNAs and miRNAs. This contract will allow Lynx to further
develop methods aimed at enhancing understanding of the
regulation of transcription and translation in many higher
organisms.
"This novel application of
MPSS(TM) represents a fundamental breakthrough for the analysis
of small RNAs," said Blake Meyers, Ph.D., co-principal
investigator on the study with Pamela Green, Ph.D. "We
anticipate that these data, as in our two previous NSF-funded
studies with Lynx, will lead to fundamental scientific advances
and publications that make a substantial contribution to the
field. Our preliminary data suggest that most small RNAs have
yet to be identified. We believe that existing methods for the
identification of small RNAs do not sample the full complexity
of small RNAs. However, we believe that MPSS(TM) will solve this
problem by allowing us to discover, analyze and sequence small
RNAs in greater depth than previously possible or economically
feasible with alternative methods."
Located in Newark, Delaware,
the University of Delaware was founded in 1743 and is a
state-assisted institution of higher learning, with more than
16,000 undergraduates and nearly 3,000 graduate students. It is
the major research university in Delaware. The Delaware
Biotechnology Institute (DBI), a unit of the University of
Delaware, is a statewide collaboration among universities, state
government, and the private sector that houses faculty from
diverse University of Delaware departments. It was founded to
help establish Delaware as a center of excellence in
biotechnology and the life sciences.
Lynx is a leader in the
development and application of novel genomic analysis solutions.
Lynx's MPSS(TM) instruments analyze millions of DNA molecules in
parallel enabling genome structure characterization at an
unprecedented level of resolution. As applied to gene expression
analysis, MPSS(TM) provides comprehensive and quantitative
digital information important to modern systems biology research
in the pharmaceutical, biotechnology and agricultural
industries.